Q1 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
FINANCIAL PROFILE
Raising 2023 guidance for Novartis excluding and including Sandoz
Expected, barring unforeseen events; growth vs. PY in cc
Previous guidance
(from low-to-mid)
Innovative Medicines
(IM)
Sales expected to grow mid single digit
Core Oplnc expected to grow high single digit to low double digit
(from mid-to-high)
Novartis ex. Sandoz
(IMCorporate)
Sales expected to grow mid single digit
(from low-to-mid)
Core Oplnc expected to grow high single digit to low double digit
(from mid-to-high)
Novartis incl. Sandoz
(IM+ Sandoz + Corporate)1
Sales expected to grow mid single digit
Core Oplnc expected to grow high single digit
(from low-to-mid)
(from mid)
Key assumptions:
Our guidance assumes that no Sandostatin® LAR generics enter in the US in 2023
■ We continue to expect that the planned Sandoz spin-off is completed in H2 2023
1. Novartis Group guidance, assuming Sandoz would remain within the Group for the entire FY 2023.
24 Investor Relations | Q1 2023 Results
NOVARTIS | Reimagining MedicineView entire presentation